Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.

被引：0
|
作者：
Cazzaniga, Marina Elena
Pronzato, Paolo
Schettini, Francesco
Del Mastro, Lucia
Riemma, Maria
Alu, Massimiliano
Turletti, Anna
Giordano, Monica
Pugliese, Palma
De Angelis, Claudia
Garrone, Ornella
Marchetti, Paolo
Riccardi, Ferdinando
Bernardo, Antonio
Livi, Lorenzo
Fabi, Alessandra
Taverniti, Cristiana
De Placido, Sabino
Mustacchi, Giorgio
机构：
[1] ASST Monza, Phase Res Unit 1, Monza, Italy
[2] San Martino IST Ist Naz Ric Cancro, Genoa, Italy
[3] Univ Naples Federico II, Naples, Italy
[4] Natl Canc Inst, IRCCS AOU San Martino IST, Dept Med Oncol, Genoa, Italy
[5] Ist Nazl Tumori IRCCS, Fdn G Pascale, Breast Oncol Unit, Naples, Italy
[6] ARNAS Civ, Med Oncol Unit, Palermo, Italy
[7] ASLTO1 Osped Martini, Med Oncol, Turin, Italy
[8] Santa Anna Hosp, Como, Italy
[9] AOS Anna UO Oncol Med, Como, Italy
[10] Osped S Chiara, ITT, AOU Pisana, Med Oncol, Pisa, Italy
[11] S Croce & Carle Teaching Hosp, Breast Unit Med Oncol, Cuneo, Italy
[12] St Andrea Univ Hosp, Dept Med Oncol, Rome, Italy
[13] Cardarelli Hosp, Breast Unit, Naples, Italy
[14] Fdn Maugeri IRCCS, Pavia, Italy
[15] Univ Florence, Florence, Italy
[16] Regina Elena Inst Canc Res, Div Med Oncol, Rome, Italy
[17] AOU Citta Salute & Sci, Med Oncol, Turin, Italy
[18] Univ Federico II Naples, Dept Clin Med & Surg, Oncol Unit, Naples, Italy
[19] Univ Trieste, Trieste, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e12528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12528
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study
    L. M. Smyth
    N. M. Iyengar
    M. F. Chen
    S. M. Popper
    S. Patil
    C. Wasserheit-Lieblich
    D. F. Argolo
    J. C. Singh
    S. Chandarlapaty
    S. M. Sugarman
    E. A. Comen
    P. R. Drullinsky
    T. A. Traina
    T. Troso-Sandoval
    J. Baselga
    L. Norton
    C. A. Hudis
    C. T. Dang
    Breast Cancer Research and Treatment, 2016, 158 : 91 - 97
  • [22] Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study
    Lecuru, F.
    Pujade-Lauraine, E.
    Hamizi, S.
    Caumont-Prim, A.
    Raban, N.
    Malaurie, E.
    Pautier, P.
    Kaminsky-Forrett, M-C.
    Meunier, J.
    Alexandre, J.
    Berton-Rigaud, D.
    Dohollou, N.
    Dubot, C.
    Floquet, A.
    Favier, L.
    Venat-Bouvet, L.
    Fabbro, M.
    Louvet, C.
    Lortholary, A.
    Ferron, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 415 - 415
  • [23] Influence of crossover therapy on the association between progression-free survival (PFS) and overall survival (OS) in randomized trials of molecular-targeted agents for advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Suzuki, E.
    Takigawa, N.
    Fujiwara, Y.
    Ichihara, E.
    Tabata, M.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Progression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center.
    Mo, Hongnan
    Xu, Binghe
    Ma, Fei
    Li, Qing
    Zhang, Pin
    Yuan, Peng
    Wang, Jiayu
    Luo, Yang
    Cai, Ruigang
    Li, Qiao
    Li, Yiqun
    Guan, Xiuwen
    Lin, Shaoyan
    Chen, Yimeng
    Wang, Zijing
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Old drugs, new opportunities Preliminary results of the VICTOR-6 study
    Cazzaniga, M.
    Cagossi, K.
    Valerio, M. R.
    Russo, S.
    Casadei, V.
    Scognamiglio, G.
    Cavanna, L.
    Toniolo, D.
    De Conciliis, E.
    Melegari, E.
    Stocchi, L.
    Gebbia, V.
    Vandone, A. M.
    Cursano, M. C.
    Pinotti, G.
    Rossello, R.
    Ortu, S.
    Pellegrino, B.
    Saracchini, S.
    Torri, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): old drugs, new results. The multicenter VICTOR-6 study
    Cazzaniga, M.
    Orlando, L.
    Melegari, E.
    Arcangeli, V.
    Butera, A.
    Pinotti, G.
    Vallini, I.
    Mocerino, C.
    Giovanardi, F.
    Cretella, E.
    Gambaro, A.
    Pistelli, M.
    Donati, S.
    Pizzuti, L.
    Spagnuolo, A.
    Putzu, C.
    Leonardi, V.
    De Angelis, C.
    Pedroli, S.
    Torri, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Assessing the correlation between second progression-free survival (PFS2) and overall survival (OS) in advanced prostate cancer patients using medical data vision (MDV) claims database in Japan
    Shiota, Masaki
    De Moor, Raf
    Koroki, Yosuke
    Yu, Dae Young
    Wu, David Bin-Chia
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (08) : 1351 - 1359
  • [28] MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)
    Goetz, M. P.
    Toi, M.
    Huober, J.
    Sohn, J.
    Tredan, O.
    Park, I. H.
    Campone, M.
    Chen, S. C.
    Sanchez, L. M. Manso
    Paluch-Shimon, S.
    van Hal, G.
    Shahir, A.
    Iwata, H.
    Johnston, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1384 - S1384
  • [29] Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1
    Bringhen, Sara
    Voorhees, Peter M.
    Plesner, Torben
    Mellqvist, Ulf-Henrik
    Reeves, Brandi
    Sonneveld, Pieter
    Byrne, Catriona
    Nordstrom, Eva
    Harmenberg, Johan
    Obermueller, Jakob
    Richardson, Paul G.
    BLOOD, 2019, 134
  • [30] Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.
    Shi, Qian
    De Gramont, Aimery
    Buyse, Marc E.
    Grothey, Axel
    Schmoll, Hans-Joachim
    Seymour, Matthew T.
    Adams, Richard A.
    Saltz, Leonard
    Goldberg, Richard M.
    Punt, Cornelis J. A.
    Douillard, Jean-Yves
    Hecht, J. Randolph
    Hurwitz, Herbert
    Diaz-Rubio, Eduardo
    Porschen, Rainer
    Tebbutt, Niall C.
    Fuchs, Charles S.
    Souglakos, John
    Falcone, Alfredo
    Sargent, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345